-+ 0.00%
-+ 0.00%
-+ 0.00%
BELITE BIO's pre-market share price fell 10.6% as the US Food and Drug Administration extended its review of eye medication.
Share
Listen to the news
BELITE BIO's pre-market share price fell 10.6% as the US Food and Drug Administration extended its review of eye medication.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending